TG Therapeutics Inc Stock, NASDAQ:TGTX
2 Gansevoort Street, 9th floor, New York, New York 10014
United States of America
Number of Employees: 272
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.